Overview of Beractant
Beractant is a pulmonary surfactant used primarily for the treatment and prevention of Respiratory Distress Syndrome (RDS) in premature infants. It is derived from bovine lung extract and contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C[2].
Market Size and Growth
The lung surfactants market, which includes beractant, is expected to witness significant growth. As of 2022, the global lung surfactants market was valued at USD 180.44 million and is projected to reach USD 245.53 million by 2030, growing at a compound annual growth rate (CAGR) of 4.0% during the forecast period of 2023-2030[1].
Key Market Drivers
Several factors are driving the growth of the lung surfactants market, including:
- Increasing Prevalence of Respiratory Distress Syndrome (RDS): The rising incidence of RDS in premature babies is a major driver, as beractant is a critical treatment for this condition[1][4].
- Government Initiatives and Support: Government support and initiatives aimed at improving neonatal care are also boosting the demand for lung surfactants[1].
- Technological Advancements: The development of new and more effective lung surfactant products, including synthetic alternatives, is further enhancing market growth[1].
Market Segmentation
By Drug Type
Beractant is one of the dominant segments in the lung surfactants market. In 2022, the lucinactant segment, which includes beractant, accounted for the highest market share. Other significant segments include colfosceril palmitate, calfactant, and poractant alfa[1].
By Indication
The respiratory distress syndrome (RDS) segment is expected to contribute significantly to the growth of the lung surfactants market during the forecast period. Other indications include respiratory infections and other related conditions[1].
By Distribution Channel
Hospital pharmacies are anticipated to contribute the largest shares to the market growth, reflecting the primary setting where beractant is administered[1].
By End User
Hospitals are the major end-users of lung surfactants, including beractant, due to the critical nature of RDS treatment in these settings[1].
Regional Outlook
- North America: This region accounted for the highest market share in 2022, with the U.S. holding 68.20% of the North American market. North America is expected to continue its dominance, reaching USD 90.82 million by 2030[1].
- Asia Pacific: This region is expected to exhibit the highest CAGR, driven by increasing healthcare infrastructure and rising demand for advanced neonatal care[1].
Competitive Landscape
The lung surfactants market is competitive, with major players such as ONY Biotech Inc, Lyomark Pharma GmbH, and Windtree Therapeutics, Inc. These companies are leveraging their technologies to develop new synthetic lung surfactants, which is expected to increase competition in the market[1].
Financial Trajectory
Current Market Value
As of 2022, the lung surfactants market, which includes beractant, was valued at USD 180.44 million[1].
Projected Market Value
By 2030, the market is expected to reach USD 245.53 million, growing at a CAGR of 4.0% during the forecast period[1].
Revenue Streams
The revenue for beractant and other lung surfactants is primarily generated through hospital pharmacies and direct sales to hospitals and specialty clinics. The increasing adoption of these surfactants in neonatal care units is a significant revenue driver[1].
Challenges and Restraints
- High Cost: The high cost of lung surfactants, including beractant, is a significant restraining factor. This can limit access to these critical treatments in some regions and among certain patient populations[1].
- Regulatory Hurdles: Strict regulatory requirements and the need for continuous clinical trials to ensure safety and efficacy can also pose challenges to market growth[4].
Future Outlook
The future of beractant and the broader lung surfactants market looks promising due to several factors:
- Technological Advancements: Continued innovation in the development of synthetic lung surfactants and improved delivery mechanisms is expected to enhance market growth[1].
- Increasing Demand: The growing need for effective treatments for RDS and other respiratory conditions in premature infants will continue to drive demand for beractant and other lung surfactants[1][4].
"Technological progression has been a critical aspect in improving the efficacy and availability of therapies for respiratory distress syndrome. These breakthroughs include recent discoveries in the area of drug delivery mechanisms, diagnostic techniques, and novel therapeutic methods to target the underlying etiological factors."[4]
Key Takeaways
- The lung surfactants market, including beractant, is expected to grow at a CAGR of 4.0% from 2023 to 2030.
- The market is driven by the increasing prevalence of RDS, government initiatives, and technological advancements.
- North America is the dominant region, but Asia Pacific is expected to show the highest growth rate.
- High costs and regulatory hurdles are significant restraining factors.
- Continued innovation and increasing demand for effective treatments will shape the future of the market.
FAQs
What is the primary use of beractant?
Beractant is used for the treatment and prevention of Respiratory Distress Syndrome (RDS) in premature infants[2].
What is the projected market size of the lung surfactants market by 2030?
The lung surfactants market is expected to reach USD 245.53 million by 2030[1].
Which region has the highest market share in the lung surfactants market?
North America has the highest market share, with the U.S. accounting for 68.20% of the North American market in 2022[1].
What are the key factors driving the growth of the lung surfactants market?
Key drivers include the increasing prevalence of RDS, government initiatives, and technological advancements in lung surfactant products[1].
What are the main restraining factors in the growth of the lung surfactants market?
High costs and regulatory hurdles are significant restraining factors in the market growth[1][4].
Sources
- Consegic Business Intelligence - Lung Surfactants Market to Hit US$ 245.53 Million By 2030[1].
- DrugBank - Beractant: Uses, Interactions, Mechanism of Action[2].
- BCC Research - Big Growth Ahead Biologic Drugs Market to Hit $823.4 Billion by 2028[3].
- Business Research Insights - Respiratory Distress Syndrome Market Size - Forecast To 2032[4].
